HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
26 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PSAP
prosaposin
Chromosome 10 Β· 10q22.1
NCBI Gene: 5660Ensembl: ENSG00000197746.16HGNC: HGNC:9498UniProt: P07602
190PubMed Papers
25Diseases
0Drugs
95Pathogenic Variants
RESEARCH IMPACT
TrendingVariant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
protease bindingprotein bindingphospholipid bindingganglioside GM1 transport to membraneGaucher disease due to saposin C deficiencyKrabbe disease due to saposin A deficiencycombined PSAP deficiencyKrabbe disease
✦AI Summary

Prosaposin (PSAP) is a lysosomal protein that serves as a precursor for saposins, which are non-enzymic cofactors essential for sphingolipid degradation in lysosomes 1. The protein is proteolytically cleaved into four saposins that facilitate the activity of hydrolytic enzymes in lysosomal degradation pathways 2. Beyond canonical lysosomal function, PSAP plays critical roles in neuronal stress responses and immune regulation. In neurons, PSAP knockdown sensitizes cells to oxidative stress by triggering lipofuscin accumulation and ferroptosis 3. PSAP mediates dendritic cell processing of apoptotic bodies for antigen presentation; however, TGF-Ξ²-induced hyperglycosylation impairs this function, promoting cancer immune escape 4. In Parkinson's disease, secreted PSAP activates GPR37 on oligodendrocytes, inducing IL-6 production that drives neuroinflammation and dopamine neuron degeneration 5. In Alzheimer's disease, PSAP signaling alters cell communications and induces astrogliosis 6. Mutations in PSAP cause rare lysosomal storage diseases including combined saposin deficiency, metachromatic leukodystrophy, and atypical Gaucher disease variants 21. PSAP-targeting approaches show therapeutic promise in tauopathies 7.

Sources cited
1
PSAP knockdown sensitizes neurons to oxidative stress via lipofuscin formation and ferroptosis
PMID: 34031600
2
PSAP mediates dendritic cell antigen presentation; hyperglycosylation impairs this function in tumors
PMID: 38207022
3
PSAP mutations cause metachromatic leukodystrophy via saposin B deficiency
PMID: 26462614
4
Secreted PSAP activates oligodendrocyte GPR37, inducing IL-6 and neurodegeneration in Parkinson's disease
PMID: 39913287
5
PSAP signaling alters cell communications and induces astrogliosis in Alzheimer's disease
PMID: 37232225
6
PSAP is proteolytically cleaved into four saposins; deficiency impairs glucocerebrosidase activity
PMID: 38928321
7
PSAP-targeting therapeutics show efficacy in tauopathies by enhancing lysosomal function
PMID: 40150858
Disease Associationsβ“˜25
Gaucher disease due to saposin C deficiencyOpen Targets
0.81Strong
Krabbe disease due to saposin A deficiencyOpen Targets
0.80Strong
combined PSAP deficiencyOpen Targets
0.79Strong
Krabbe diseaseOpen Targets
0.63Moderate
Parkinson diseaseOpen Targets
0.62Moderate
metachromatic leukodystrophyOpen Targets
0.59Moderate
neurodegenerative diseaseOpen Targets
0.57Moderate
lysosomal storage diseaseOpen Targets
0.54Moderate
Alzheimer diseaseOpen Targets
0.54Moderate
multiple sclerosisOpen Targets
0.53Moderate
genetic disorderOpen Targets
0.45Moderate
metachromatic leukodystrophy, juvenile formOpen Targets
0.38Weak
metachromatic leukodystrophy, adult formOpen Targets
0.38Weak
infantile Krabbe diseaseOpen Targets
0.37Weak
metachromatic leukodystrophy, late infantile formOpen Targets
0.37Weak
Hereditary late-onset Parkinson diseaseOpen Targets
0.35Weak
late-onset Parkinson diseaseOpen Targets
0.34Weak
pericarditisOpen Targets
0.27Weak
neuromuscular diseaseOpen Targets
0.15Weak
deafnessOpen Targets
0.14Weak
Combined saposin deficiencyUniProt
Gaucher disease, atypical, due to saposin C deficiencyUniProt
Krabbe disease, atypical, due to saposin A deficiencyUniProt
Metachromatic leukodystrophy due to saposin B deficiencyUniProt
Parkinson disease 24, autosomal dominantUniProt
Pathogenic Variants95
NM_002778.4(PSAP):c.645C>A (p.Asn215Lys)Pathogenic
Sphingolipid activator protein 1 deficiency|Metachromatic leukodystrophy|Krabbe disease due to saposin A deficiency;Parkinson disease 24, autosomal dominant, susceptibility to;Sphingolipid activator protein 1 deficiency;Gaucher disease due to saposin C deficiency;Combined PSAP deficiency|Parkinson disease 24, autosomal dominant, susceptibility to
β˜…β˜…β˜†β˜†2026β†’ Residue 215
NM_002778.4(PSAP):c.1076A>C (p.Glu359Ala)Pathogenic
Metachromatic leukodystrophy|Gaucher disease due to saposin C deficiency|Sphingolipid activator protein 1 deficiency
β˜…β˜…β˜†β˜†2026β†’ Residue 359
NM_002778.4(PSAP):c.1005+1G>APathogenic
Gaucher disease due to saposin C deficiency|Sphingolipid activator protein 1 deficiency|Combined PSAP deficiency|Combined PSAP deficiency;Krabbe disease due to saposin A deficiency;Sphingolipid activator protein 1 deficiency;Parkinson disease 24, autosomal dominant, susceptibility to;Gaucher disease due to saposin C deficiency|Metachromatic leukodystrophy|not provided
β˜…β˜…β˜†β˜†2025
NM_002778.4(PSAP):c.643A>C (p.Asn215His)Pathogenic
Sphingolipid activator protein 1 deficiency|PSAP-related disorder|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2025β†’ Residue 215
NM_002778.4(PSAP):c.650C>T (p.Thr217Ile)Pathogenic
Sphingolipid activator protein 1 deficiency|Inborn genetic diseases|not provided|Parkinson disease 24, autosomal dominant, susceptibility to;Combined PSAP deficiency;Sphingolipid activator protein 1 deficiency;Krabbe disease due to saposin A deficiency;Gaucher disease due to saposin C deficiency|Parkinson disease 24, autosomal dominant, susceptibility to|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2025β†’ Residue 217
NM_002778.4(PSAP):c.576+1G>ALikely pathogenic
Sphingolipid activator protein 1 deficiency|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2025
NM_002778.4(PSAP):c.2T>G (p.Met1Arg)Pathogenic
Sphingolipid activator protein 1 deficiency|not provided|Parkinson disease 24, autosomal dominant, susceptibility to
β˜…β˜…β˜†β˜†2025β†’ Residue 1
NM_002778.4(PSAP):c.1A>T (p.Met1Leu)Pathogenic
Combined PSAP deficiency|Gaucher disease due to saposin C deficiency|Sphingolipid activator protein 1 deficiency|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2025β†’ Residue 1
NM_002778.4(PSAP):c.607C>T (p.Gln203Ter)Pathogenic
not provided|Sphingolipid activator protein 1 deficiency|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2025β†’ Residue 203
NM_002778.4(PSAP):c.1A>G (p.Met1Val)Pathogenic
Sphingolipid activator protein 1 deficiency|Metachromatic leukodystrophy|Parkinson disease 24, autosomal dominant, susceptibility to
β˜…β˜…β˜†β˜†2024β†’ Residue 1
NM_002778.4(PSAP):c.722_723delinsAA (p.Cys241Ter)Pathogenic
Sphingolipid activator protein 1 deficiency|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2024β†’ Residue 241
NM_002778.4(PSAP):c.577-1G>TPathogenic
Sphingolipid activator protein 1 deficiency|Parkinson disease 24, autosomal dominant, susceptibility to|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2024
NM_002778.4(PSAP):c.889G>T (p.Glu297Ter)Pathogenic
Sphingolipid activator protein 1 deficiency|Metachromatic leukodystrophy
β˜…β˜…β˜†β˜†2024β†’ Residue 297
NM_002778.4(PSAP):c.679_681del (p.Lys227del)Pathogenic
Sphingolipid activator protein 1 deficiency|Combined PSAP deficiency|Metachromatic leukodystrophy|Krabbe disease due to saposin A deficiency;Sphingolipid activator protein 1 deficiency;Parkinson disease 24, autosomal dominant, susceptibility to;Combined PSAP deficiency;Gaucher disease due to saposin C deficiency|PSAP-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 227
NM_002778.4(PSAP):c.148C>T (p.Gln50Ter)Pathogenic
Sphingolipid activator protein 1 deficiency|Combined PSAP deficiency;Krabbe disease due to saposin A deficiency;Sphingolipid activator protein 1 deficiency;Parkinson disease 24, autosomal dominant, susceptibility to;Gaucher disease due to saposin C deficiency
β˜…β˜…β˜†β˜†2024β†’ Residue 50
NM_002778.4(PSAP):c.722G>C (p.Cys241Ser)Pathogenic
Sphingolipid activator protein 1 deficiency|Combined PSAP deficiency|Parkinson disease 24, autosomal dominant, susceptibility to
β˜…β˜…β˜†β˜†2024β†’ Residue 241
NM_002778.4(PSAP):c.828_829del (p.Glu276fs)Pathogenic
Sphingolipid activator protein 1 deficiency|not provided|Krabbe disease due to saposin A deficiency;Gaucher disease due to saposin C deficiency;Parkinson disease 24, autosomal dominant, susceptibility to;Combined PSAP deficiency;Sphingolipid activator protein 1 deficiency
β˜…β˜…β˜†β˜†2023β†’ Residue 276
NM_002778.4(PSAP):c.720+2_720+5delLikely pathogenic
not provided|Sphingolipid activator protein 1 deficiency
β˜…β˜…β˜†β˜†2022
NM_002778.4(PSAP):c.721-1G>ALikely pathogenic
Sphingolipid activator protein 1 deficiency|Krabbe disease due to saposin A deficiency
β˜…β˜…β˜†β˜†2019
NM_002778.4(PSAP):c.816_823del (p.Asp272fs)Pathogenic
not provided|Sphingolipid activator protein 1 deficiency
β˜…β˜†β˜†β˜†2026β†’ Residue 272
View on ClinVar β†—
Related Genes
JUNProtein interaction100%CHIT1Protein interaction99%GPR37Protein interaction99%SORT1Protein interaction97%MYLIPProtein interaction92%ARSAProtein interaction91%
Tissue Expression6 tissues
Heart
100%
Lung
71%
Brain
68%
Bone Marrow
60%
Ovary
52%
Liver
44%
Gene Interaction Network
Click a node to explore
PSAPJUNCHIT1GPR37SORT1MYLIPARSA
PROTEIN STRUCTURE
Preparing viewer…
PDB3BQP Β· 1.30 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.51Moderately Constrained
pLIβ“˜
0.95Intolerant
Observed/Expected LoF0.36 [0.26–0.51]
RankingsWhere PSAP stands among ~20K protein-coding genes
  • #2,254of 20,598
    Most Researched190 Β· top quartile
  • #809of 5,498
    Most Pathogenic Variants95 Β· top quartile
  • #3,076of 17,882
    Most Constrained (LOEUF)0.51 Β· top quartile
Genes detectedPSAP
Sources retrieved26 papers
Response timeβ€”
πŸ“„ Sources
26β–Ό
1
Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis.
PMID: 34031600
Nat Neurosci Β· 2021
1.00
2
Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape.
PMID: 38207022
Science Β· 2024
0.90
3
ACE-mediated Glycosylation Stabilizes PSAP To Promote GPR37-dependent Macrophage-Nucleus Pulposus Cells Crosstalk and TGFΞ² Signaling in Alleviating Intervertebral Disc Degeneration.
PMID: 41085015
Adv Sci (Weinh) Β· 2025
0.80
4
Mutation Update of ARSA and PSAP Genes Causing Metachromatic Leukodystrophy.
PMID: 26462614
Hum Mutat Β· 2016
0.80
5
Cellular Lyso-Gb3 Is a Biomarker for Mucolipidosis II.
PMID: 40650054
Int J Mol Sci Β· 2025
0.76